What is the drug of choice for the treatment of peptic ulcer caused due to chronic use of NSAIDs?
Which derivative of morphine is used for the treatment of diarrhea?
All of the following are antiemetics except?
Which 5-HT receptor subtype acts as the primary emesis receptor?
Omeprazole is a
Granisetron has antiemetic properties because of which of the following actions?
What is the mechanism of action of cisapride?
What is the primary action of sucralfate?
Which drug is used in the treatment of gastric ulcer due to H. pylori?
What is the primary pharmacological action of Metoclopramide?
Explanation: **Explanation:** The treatment and prevention of NSAID-induced peptic ulcers depend on whether the NSAID can be discontinued. In clinical practice, **Proton Pump Inhibitors (PPIs)** like **Esomeprazole** are the **drug of choice** for both the healing and prevention of NSAID-induced ulcers. They are superior to H2 blockers and mucosal protective agents because they provide rapid symptomatic relief and faster ulcer healing by maintaining a gastric pH > 4. **Analysis of Options:** * **Esomeprazole (Option D):** As a PPI, it irreversibly inhibits the $H^+/K^+$ ATPase pump. It is more effective than Misoprostol in healing existing ulcers and is better tolerated by patients, making it the first-line recommendation. * **Misoprostol (Option C):** This is a $PGE_1$ analogue. While it is the **specific** drug for preventing NSAID-induced ulcers (by replacing the prostaglandins inhibited by NSAIDs), it is **not** the drug of choice for treatment due to frequent side effects like abdominal cramps and diarrhea. * **Loxatidine (Option B):** An $H_2$ receptor antagonist. While effective for simple peptic ulcers, $H_2$ blockers are less effective than PPIs for NSAID-induced ulcers, especially if the patient must continue taking the NSAID. * **Pirenzepine (Option A):** An $M_1$ selective anticholinergic. It is rarely used today due to low efficacy and significant side effects (dry mouth, blurred vision) compared to modern acid suppressants. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for Treatment:** PPIs (e.g., Esomeprazole, Omeprazole). * **Most Specific Drug for Prevention:** Misoprostol (but PPIs are preferred clinically due to better compliance). * **Mechanism of NSAID Ulcers:** Inhibition of COX-1 leads to decreased synthesis of protective prostaglandins ($PGE_2$ and $PGI_2$). * **Contraindication:** Misoprostol is strictly contraindicated in pregnancy as it can cause uterine contractions and abortion.
Explanation: **Explanation:** **Diphenoxylate** is the correct answer because it is a synthetic opioid derivative specifically designed for its anti-diarrheal properties. It acts primarily on the **$\mu$-opioid receptors** in the gastrointestinal tract, decreasing intestinal motility and increasing the transit time of luminal contents. This allows for greater water absorption, thereby thickening the stool. * **Why Diphenoxylate?** Unlike morphine, diphenoxylate has poor CNS penetration at therapeutic doses, making it less likely to cause analgesia or euphoria. It is commonly formulated with a sub-therapeutic dose of **Atropine** (Lomotil) to discourage abuse, as higher doses would cause unpleasant anticholinergic side effects. **Analysis of Incorrect Options:** * **Oxymorphine:** A potent semi-synthetic opioid analgesic. While it causes constipation as a side effect, it is not used clinically to treat diarrhea due to its high addictive potential and CNS effects. * **Pethidine (Meperidine):** A phenylpiperidine derivative used primarily for analgesia (especially in labor and biliary colic). It is not indicated for diarrhea. * **Codeine:** While codeine is an opioid that causes significant constipation, its primary clinical uses are as an analgesic and an antitussive (cough suppressant). **High-Yield Clinical Pearls for NEET-PG:** * **Loperamide** is another morphine derivative used for diarrhea. It is preferred over diphenoxylate because it does not cross the blood-brain barrier at all (due to P-glycoprotein efflux), resulting in **zero abuse potential**. * **Mechanism:** Opioids inhibit the release of Acetylcholine from the myenteric plexus, leading to decreased peristalsis. * **Contraindication:** Anti-diarrheals should be avoided in **infectious diarrhea** (e.g., *Salmonella*, *Shigella*) as they may delay the clearance of toxins and lead to toxic megacolon.
Explanation: **Explanation:** The correct answer is **D. Bismuth**. Bismuth subsalicylate is a mucosal protective agent used primarily in the treatment of peptic ulcer disease (as part of quadruple therapy for *H. pylori*), traveler’s diarrhea, and dyspepsia. It does not possess antiemetic properties. **Why the other options are incorrect:** * **Ondansetron (Option A):** A potent **5-HT3 receptor antagonist**. It acts both peripherally on vagal nerve terminals and centrally in the Chemoreceptor Trigger Zone (CTZ). It is the gold standard for preventing chemotherapy-induced nausea and vomiting (CINV) and post-operative vomiting. * **Metoclopramide (Option B):** A **D2 receptor antagonist** with prokinetic properties. It increases lower esophageal sphincter tone and gastric emptying. It is commonly used for gastroparesis and as a general antiemetic. * **Chlorpromazine (Option C):** A typical antipsychotic that acts as a **D2 antagonist** in the CTZ. While primarily a neuroleptic, it is clinically used to treat severe nausea and intractable hiccups. **High-Yield Clinical Pearls for NEET-PG:** * **Bismuth Side Effects:** Can cause harmless **blackening of the tongue and stools**, which may be mistaken for melena. * **Drug of Choice (DOC):** * **Motion Sickness:** Hyoscine (Scopolamine) - Prophylactic. * **Morning Sickness (Pregnancy):** Doxylamine + Pyridoxine. * **Cancer Chemotherapy (Acute):** Ondansetron + Dexamethasone. * **Cancer Chemotherapy (Delayed):** Aprepitant (NK1 receptor antagonist). * **Metoclopramide Warning:** Can cause **Extrapyramidal Side Effects (EPS)** like acute dystonia, especially in children and young adults, due to central D2 blockade.
Explanation: **Explanation:** The correct answer is **5-HT3**. **Why 5-HT3 is the primary emesis receptor:** The 5-HT3 receptor is a ligand-gated ion channel located in three critical areas involved in the vomiting reflex: the **Chemoreceptor Trigger Zone (CTZ)** in the area postrema, the **Nucleus Tractus Solitarius (NTS)**, and on **vagal afferents** in the gastrointestinal tract. When cytotoxic drugs (chemotherapy) damage enterochromaffin cells in the gut, they release massive amounts of serotonin. This serotonin stimulates 5-HT3 receptors on vagal nerves, sending signals to the brain's vomiting center. Consequently, 5-HT3 antagonists (e.g., **Ondansetron**) are the first-line drugs for preventing Chemotherapy-Induced Nausea and Vomiting (CINV). **Why other options are incorrect:** * **5-HT1:** These receptors (specifically 5-HT1A/1B/1D) are primarily involved in neurotransmission in the CNS and vasoconstriction of cranial blood vessels. They are the targets for **Triptans** used in migraine, not emesis. * **5-HT2:** These receptors are involved in platelet aggregation, smooth muscle contraction, and hallucinations (LSD target). They do not play a significant role in the emetic pathway. * **5-HT4:** These receptors are located in the GI tract and facilitate the release of acetylcholine. 5-HT4 **agonists** (e.g., Prucalopride, Tegaserod) act as **prokinetic agents** to increase gut motility, rather than acting as primary emetic triggers. **High-Yield Clinical Pearls for NEET-PG:** * **Ondansetron** is the prototype 5-HT3 antagonist. Its most common side effects are **headache** and **constipation**. * A significant ECG side effect of 5-HT3 antagonists is **QT interval prolongation**. * For highly emetogenic chemotherapy, 5-HT3 antagonists are often combined with **Dexamethasone** and **Aprepitant** (NK1 receptor antagonist) for synergistic effect.
Explanation: **Explanation:** **Correct Answer: B. Proton pump inhibitor** Omeprazole is the prototype of the **Proton Pump Inhibitors (PPIs)**. It is a substituted benzimidazole that acts as a prodrug. Once absorbed, it reaches the parietal cells of the stomach via the bloodstream, where it is converted into its active sulfenamide form in the acidic environment of the canaliculi. It then binds **irreversibly** to the **H+/K+ ATPase enzyme** (the "proton pump"), which is the final common pathway of gastric acid secretion. This results in a potent and long-lasting inhibition of both basal and stimulated acid secretion. **Analysis of Incorrect Options:** * **A. Antihistamine:** While H2-receptor antagonists (like Ranitidine) block histamine-induced acid secretion, Omeprazole does not act on histamine receptors. * **C. Ulcer protective:** These are drugs like Sucralfate or Bismuth salts that form a physical barrier over the ulcer base to prevent acid/pepsin damage. They do not inhibit acid secretion. * **D. Ulcer healing drug:** While PPIs do facilitate ulcer healing, this is a therapeutic *outcome* rather than the pharmacological *classification*. In medical exams, the mechanism-based classification (PPI) is the preferred answer. **High-Yield Clinical Pearls for NEET-PG:** * **Administration:** PPIs should be taken **30–60 minutes before breakfast** for maximum efficacy, as the number of H+/K+ ATPase pumps is highest after a period of fasting. * **Drug Interactions:** Omeprazole inhibits **CYP2C19**, which can decrease the activation of the antiplatelet drug **Clopidogrel**. Pantoprazole is the preferred PPI in patients on Clopidogrel. * **Long-term Side Effects:** Chronic use is associated with Vitamin B12 deficiency, hypomagnesemia, and an increased risk of *C. difficile* infections and osteoporotic fractures (due to decreased calcium absorption).
Explanation: **Explanation:** **Granisetron** is a potent, highly selective **5-HT₃ (Serotonin) receptor antagonist**. The correct answer is **D** because its antiemetic mechanism involves blocking serotonin receptors both peripherally (on vagal nerve terminals in the gastrointestinal tract) and centrally (in the Chemoreceptor Trigger Zone - CTZ). When cytotoxic drugs or radiation damage the intestinal mucosa, enterochromaffin cells release serotonin. This serotonin stimulates 5-HT₃ receptors, sending emetic signals to the brain. By blocking these receptors, Granisetron effectively prevents nausea and vomiting, particularly in the context of chemotherapy. **Analysis of Incorrect Options:** * **Option A (Dopaminergic blocking):** This is the mechanism of drugs like **Metoclopramide** and **Domperidone** (D₂ blockers). While effective antiemetics, Granisetron does not act on dopamine receptors. * **Options B & C (GABA actions):** GABAergic pathways are generally not the primary target for standard antiemetics. Benzodiazepines (like Lorazepam) may be used as adjuncts for *anticipatory* vomiting due to their sedative/anxiolytic effects, but Granisetron has no GABA-mimetic or inhibitory activity. **High-Yield Clinical Pearls for NEET-PG:** * **Drug Class:** Granisetron belongs to the "-setron" family (Ondansetron, Palonosetron, Dolasetron). * **DOC:** 5-HT₃ antagonists are the **Drug of Choice** for Chemotherapy-Induced Nausea and Vomiting (CINV) and Post-Operative Nausea and Vomiting (PONV). * **Side Effects:** The most common side effects are **headache** and **constipation**. * **ECG Changes:** They can cause **QT interval prolongation** (caution in patients with cardiac arrhythmias). * **Palonosetron** is the longest-acting drug in this class.
Explanation: **Explanation:** **Mechanism of the Correct Answer (D):** Cisapride is a **prokinetic agent** that primarily acts as a **selective 5-HT4 receptor agonist**. These receptors are located on the presynaptic terminals of enteric cholinergic neurons. Activation of 5-HT4 receptors stimulates the release of **Acetylcholine (ACh)** at the myenteric plexus (Auerbach's plexus). Increased ACh levels enhance gastrointestinal motility and increase Lower Esophageal Sphincter (LES) tone without stimulating gastric acid secretion. **Analysis of Incorrect Options:** * **Option A (D2 Inhibition):** This is the mechanism of **Metoclopramide** and **Domperidone**. While Metoclopramide also has 5-HT4 agonist properties, Cisapride is distinct because it lacks D2 receptor antagonism, meaning it does not cause extrapyramidal side effects or hyperprolactinemia. * **Option B (5-HT3 Antagonism):** This is the mechanism of **Ondansetron**, used primarily as an antiemetic. While Cisapride has weak 5-HT3 antagonistic properties, its prokinetic effect is strictly due to 5-HT4 agonism. * **Option C (5-HT4 Antagonism):** This would inhibit GI motility. An example of a 5-HT4 antagonist is **Prucalopride** (though it is actually a succinate agonist used for constipation; true antagonists are rarely used clinically). **High-Yield Clinical Pearls for NEET-PG:** * **Cardiac Toxicity:** Cisapride is notorious for causing **QT interval prolongation** and **Torsades de Pointes** by blocking HERG K+ channels. This led to its withdrawal or restricted use in many countries. * **Drug Interactions:** It is metabolized by **CYP3A4**. Co-administration with CYP3A4 inhibitors (e.g., Ketoconazole, Erythromycin) increases its plasma levels, significantly raising the risk of fatal arrhythmias. * **Comparison:** Unlike Metoclopramide, Cisapride acts throughout the GI tract, including the colon.
Explanation: **Explanation:** **Sucralfate** is a complex salt of sucrose octasulfate and aluminum hydroxide. Its primary mechanism of action is **cytoprotection** rather than altering gastric pH. 1. **Why Option C is Correct:** In an acidic environment (pH < 4), sucralfate undergoes polymerization to form a sticky, viscid gel. This paste has a strong negative charge and binds to positively charged proteins (albumin, fibrinogen) exposed in the **ulcer base**. It creates a physical barrier (a "chemical bandage") that protects the ulcer from acid, pepsin, and bile salts, allowing the mucosa to heal. It also stimulates local prostaglandin production and binds to fibroblast growth factors (FGF), further aiding mucosal repair. 2. **Why Other Options are Incorrect:** * **Option A:** Sucralfate does not inhibit the proton pump or H2 receptors; therefore, it does not reduce acid secretion. * **Option B:** While it contains aluminum hydroxide, its acid-neutralizing capacity is clinically insignificant at therapeutic doses. * **Option C:** It has no intrinsic antimicrobial activity against *H. pylori*. **High-Yield Clinical Pearls for NEET-PG:** * **Activation Requirement:** It requires an **acidic medium** for activation. Therefore, it should **not** be given with antacids, H2 blockers, or PPIs (which raise gastric pH). * **Administration:** It should be taken on an empty stomach, 1 hour before meals. * **Side Effects:** The most common side effect is **constipation** (due to the aluminum content). * **Drug Interactions:** It can adsorb other drugs (e.g., phenytoin, digoxin, tetracycline, ciprofloxacin), reducing their absorption. Maintain a 2-hour gap. * **Indication:** Primarily used in duodenal ulcers and for prophylaxis of stress ulcers in critically ill patients.
Explanation: **Explanation:** **Bismuth subcitrate** is the correct answer because it is a key component of the multi-drug regimens used to eradicate *Helicobacter pylori*. Its mechanism of action is two-fold: it provides a **cytoprotective coating** over the ulcer base (protecting it from acid and pepsin) and, crucially, it exerts **direct antimicrobial activity** against *H. pylori* by inhibiting its enzymes and preventing bacterial adhesion to the gastric mucosa. It is most commonly used in "Bismuth-based Quadruple Therapy" (Bismuth + PPI + Metronidazole + Tetracycline). **Analysis of Incorrect Options:** * **Anticholinergics (A):** While drugs like pirenzepine reduce gastric acid secretion by blocking M1 receptors, they have no effect on *H. pylori* and are largely obsolete due to the superior efficacy of PPIs. * **Carbenoxolone sodium (B):** Derived from licorice, this drug promotes mucus production and increases the lifespan of gastric mucosal cells. However, it does not have antibacterial properties and is rarely used today due to mineralocorticoid-like side effects (hypertension, edema). * **Corticosteroids (D):** These are contraindicated in peptic ulcer disease as they inhibit prostaglandin synthesis, which impairs the gastric mucosal barrier and can actually *induce* or worsen ulcers. **NEET-PG High-Yield Pearls:** * **Colloidal Bismuth Subcitrate (CBS):** Can cause harmless black discoloration of the tongue and stools, which may be mistaken for melena. * **First-line Triple Therapy:** PPI + Amoxicillin + Clarithromycin (mnemonic: **PAC**). * **H. pylori** is a Gram-negative, spiral-shaped bacterium that produces **urease**, a feature used for diagnosis (Urea Breath Test).
Explanation: ### Explanation **Metoclopramide** is a substituted benzamide categorized as a **prokinetic agent**. Its primary pharmacological action is mediated through two main mechanisms: **D2 receptor antagonism** (central and peripheral) and **5-HT4 receptor agonism**. **Why Option B is Correct:** Metoclopramide exerts its prokinetic effect by blocking D2 receptors in the gastrointestinal tract, which normally inhibit acetylcholine release. By removing this inhibition, it increases the release of acetylcholine from myenteric neurons. This leads to: 1. **Increased Lower Esophageal Sphincter (LES) tone/pressure** (preventing reflux). 2. Increased gastric antral contractions and improved gastroduodenal coordination. 3. Accelerated gastric emptying. **Why Other Options are Incorrect:** * **Option A:** Metoclopramide **enhances** (rather than inhibits) cholinergic stimulation. Drugs like atropine or hyoscine inhibit cholinergic stimulation. * **Option C:** Metoclopramide **antagonizes** (blocks) D2 receptors. It does not stimulate them. Its central D2 antagonism in the Chemoreceptor Trigger Zone (CTZ) provides its antiemetic property. * **Option D:** Metoclopramide has **minimal to no effect on colonic motility**. Its actions are primarily limited to the upper GI tract (esophagus, stomach, and duodenum). **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** For Diabetic Gastroparesis and as an antiemetic in post-operative vomiting. * **Adverse Effects:** Due to central D2 blockade, it can cause **Extrapyramidal Symptoms (EPS)** like acute dystonia, Parkinsonism, and Akathisia. It also causes **Hyperprolactinemia** (leading to galactorrhea/gynecomastia). * **Contraindication:** Should be avoided in patients with **Mechanical Bowel Obstruction** or Pheochromocytoma (can cause hypertensive crisis).
Acid-Peptic Disease Therapeutics
Practice Questions
Proton Pump Inhibitors
Practice Questions
H2 Receptor Antagonists
Practice Questions
Antacids and Mucosal Protectants
Practice Questions
Antiemetics
Practice Questions
Prokinetic Agents
Practice Questions
Laxatives and Purging Agents
Practice Questions
Antidiarrheal Drugs
Practice Questions
Drugs for Inflammatory Bowel Disease
Practice Questions
Pancreatic Enzyme Supplements
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free